Truist analyst Jailendra Singh upgraded Doximity (DOCS) to Buy from Hold with a $62 price target Doximity continues to gain market share and outperform the HCP pharma digital marketing industry, with its OpenEvidence tools showing promise despite adoption still developing, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
- Doximity upgraded to Buy from Hold at Truist
- Doximity price target lowered to $60 from $75 at KeyBanc
- Doximity price target lowered to $48 from $58 at Canaccord
- Doximity price target raised to $50 from $48 at Canaccord
- Doximity: Compelling Long Opportunity Amid Overdone Competitive Fears and Undervalued AI-Driven Growth